European Launch of ResistancePlus MG FleXible for the GeneXpert System
16.12.2019 10:00:00 EET | Business Wire | Press release
SpeeDx Pty, Ltd. today announced the European launch of Resistance Plus® MG FleXible, the first sample-to-answer test for detecting the sexually transmitted infection (STI) Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance. Cepheid is the exclusive distribution partner of this test, available through Cepheid’s FleXible Cartridge programme for the GeneXpert System.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191215005039/en/
ResistancePlus MG FleXible is now selling in France and the U.K. (to be followed by rest of EU, Australia and New Zealand). This successful collaboration between SpeeDx and Cepheid is the first sample-to-answer test for Mgen and macrolide resistance - exclusively distributed by Cepheid. (Photo: Business Wire)
Management guidelines around the world, including those recently updated in France1 and the U.K.2, reference testing the macrolide resistance status of Mgen infections in order to more effectively treat patients. Mgen can cause symptoms such as urethritis, cervicitis, endometritis and pelvic inflammatory disease, and has been linked to reproductive health complications including pre-term birth and infertility.2,3 Due to the challenges of rising antimicrobial resistance and a lack of clear data that asymptomatic infection leads to protracted health complications, Mgen testing guidelines are unanimous in their recommendation to only test symptomatic individuals.
“This is an important test expansion for the thousands of GeneXpert Systems on the market,” said Colin Denver, SpeeDx CEO. “ Resistance Plus MG FleXible enables Resistance Guided Therapy, supporting more clinicians to adhere to testing guidelines and maximising effective care for their patients infected with Mgen.”
Both SpeeDx and Cepheid will be showcasing Resistance Plus MG at RICAI (Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse) December 15th and 16th in Paris. Visit SpeeDx booth #41bis and Cepheid booth #18 to learn more.
About SpeeDx
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities. The company is based in Australia with offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. The SpeeDx Resistance Plus® MG open-platform assay is CE marked for sale in Europe, TGA approved for sale in Australia and clinical trials are being finalised for submission to the U.S. FDA. Products in the SpeeDx portfolio focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.
For more information on SpeeDx please see: https://plexpcr.com
- https://www.sfdermato.org/site/groupe-infectiologie-dermatologique-et-infections-sexuellement-transmissibles.html
- https://www.bashhguidelines.org/media/1146/ngu-update-05_2017-final.pdf
- http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191215005039/en/
Contact information
SpeeDx:
Europe, Australia, New Zealand:
Madeline O’Donoghue
+61 2 9209 4170
madelineo@speedx.com.au
Cepheid:
Darwa Peterson
darwa@cepheid.com
Tel. + 1.408.400.4324
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Actiphy Inc. Unveils Actiphy ImageReplicator™15.6.2026 18:00:00 EEST | Press release
Actiphy Inc., a leading provider of backup, disaster recovery, and virtualization software, today announced the release of Actiphy ImageReplicator, a dedicated replication solution for ActiveImage Protector backup images. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615886945/en/ Actiphy ImageReplicator dashboard displaying centralized replication management, job status, replication history, and retention monitoring across protected backup images. As ransomware attacks, cyber threats, and infrastructure failures continue to grow in frequency and sophistication, organizations need reliable ways to protect backup data from loss, corruption, and unauthorized access. When primary systems are compromised, backup data becomes the final line of defense for maintaining business continuity and ensuring rapid recovery. Organizations increasingly rely on 3-2-1 backup strategies that include offsite and immutable copies of critical
Energy Dome and SRP to Add Long-Duration Energy Storage Project to the Grid, Expand Google Collaboration15.6.2026 16:30:00 EEST | Press release
Energy Dome, a leading provider of innovative capacity solutions for utilities and AI infrastructure, and Salt River Project (SRP), a not-for-profit public power utility serving the greater Phoenix metropolitan area, today announced an agreement to add a 19 megawatt (MW), 10-hour carbon dioxide-based (CO2) battery system to the grid. The project is planned to be co-located on the site of SRP’s Coronado Generating Station (CGS) in St. Johns, Arizona, and it will be developed under a 20-year tolling agreement, with Energy Dome owning and operating the facility and SRP dispatching its output. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615027901/en/ Image: Rendering of Energy Dome’s energy storage system located at the Coronado Generating Station site The project is also part of Google and SRP’s innovative collaboration to accelerate deployment of non-lithium-ion long-duration energy storage (LDES) technologies that suppo
SLB Launches Digital Marketplace to Scale AI and Digital Innovation Across Energy15.6.2026 15:15:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced the launch of the SLB Digital Marketplace, a curated digital destination designed to help energy companies rapidly discover and deploy specialized AI agents, domain models, skills, tools, data connectors and digital applications within their existing digital environments. The SLB Digital Marketplace extends the company’s open platform strategy to its Tela™ agentic AI assistant by enabling SLB, partners, independent software vendors (ISVs), developers and customers to bring purpose-built digital capabilities to the energy industry through a single, governed channel. All marketplace offerings are certified against SLB standards for security, interoperability and compatibility before listing. The launch comes as the industry moves toward agentic AI — where software can reason, act and automate across complex technical workflows. As these capabilities proliferate, energy companies will need access to a broader ecosystem of sp
Thales at Eurosatory 2026: Ready today. Ready tomorrow15.6.2026 15:01:00 EEST | Press release
As Eurosatory 2026 opens its doors, Thales is pleased to share with you a complete overview of the announcements that will be made during the first day of this international defense and security show. This document centralises all our news, innovations and partnerships, released on June, 15th, 2026 with direct links to the associated press releases: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615204020/en/ Thales at Eurosatory 2026: Ready today. Ready tomorrow. Thales unveils new AI-powered training data analytics platform to enhance military training.Thales launches next-generation 70mm laser-guided rocket dedicated for counter-drone operations.Thales unveils next-generation Bushmaster Mulga Utility Variant.Thales launches RapidStriker, a complete system for protection against drones.Renault Group and Thales unveil 4 TROOP, an innovative tactical vehicle for future land forces engagements. Thales press releases will b
Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery15.6.2026 15:00:00 EEST | Press release
Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory animal care and use. The accreditation reflects Biocytogen’s continued commitment to maintaining the highest standards of animal welfare, scientific integrity, and operational excellence across its preclinical research and drug discovery activities. Biocytogen’s Boston facility serves as a key hub supporting the company’s expanding portfolio of drug discovery and translational research capabilities. The facility enables a broad range of in vivo studies supporting antibody therapeutics, multispecific antibodies, ADCs, cell therapies, and other innovative biologics programs for pharmaceutical and biotechnology partners worldwide. Through its proprietary BioMice™ platform, Biocytogen has established one of the industry’s most comprehensive collections of genetically engineered disease mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom